Valuation: Cutia Therapeutics

Market Cap 342M 400M 50.94M 44.95M 42.53M 38.57M 72.32M 4.89B 73.03M 510M 197M 2.5B 191M 187M 8.03B P/E 2026 *
31.4x
P/E 2027 * 6.72x
Enterprise Value 342M 400M 50.94M 44.95M 42.53M 38.57M 72.32M 4.89B 73.03M 510M 197M 2.5B 191M 187M 8.03B EV / Sales 2026 *
0.58x
EV / Sales 2027 * 0.36x
Free-Float
32.66%
Yield 2026 *
-
Yield 2027 * -
1 day+22.22%
1 week-7.56%
Current month-42.41%
1 month-43.73%
3 months-59.26%
6 months-76.89%
Current year-75.77%
1 week 0.74
Extreme 0.74
1.33
1 month 0.74
Extreme 0.74
1.97
Current year 0.74
Extreme 0.74
5.51
1 year 0.74
Extreme 0.74
9.19
3 years 0.74
Extreme 0.74
24
5 years 0.74
Extreme 0.74
32.6
10 years 0.74
Extreme 0.74
32.6
Manager TitleAgeSince
Chief Executive Officer 48 2019-08-31
Director of Finance/CFO 36 2021-05-09
Chief Tech/Sci/R&D Officer 42 2020-01-09
Director TitleAgeSince
Director/Board Member 48 2020-05-11
Chairman 63 2019-08-22
Director/Board Member 36 2022-11-14
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/24 Other

Founder

15,000 0.0049%
10/3/24 Other

Chief Financial Officer

20,000 0.0066%
10/2/24 Other

Chief Financial Officer

30,000 0.0098%
Change 5-day change 1-year change 3-year change Capi.($)
+22.22%-7.56%-87.40%-94.42% 41.69M
-0.07%+1.24%+63.06%+120.55% 1,056B
-1.66%-0.75%+47.11%+71.54% 655B
-1.21%-0.61%+18.11%+76.83% 471B
-1.72%-4.06%+36.39%+39.47% 342B
-0.40%+3.83%+22.08%+28.82% 277B
-0.51%-1.93%+12.09%+11.94% 257B
+1.28%+3.11%+54.40%+57.39% 226B
-0.56%-0.60%+34.75%+102.51% 189B
-0.24%-2.76%-28.41%-60.92% 170B
Average +1.72%-1.56%+17.22%+35.37% 364.29B
Weighted average by Cap. -0.66%+1.04%+38.90%+70.52%

Financials

2026 *2027 *
Net sales 588M 688M 87.62M 77.33M 73.16M 66.35M 124M 8.41B 126M 878M 338M 4.29B 329M 322M 13.82B 961M 1.12B 143M 126M 120M 108M 203M 13.74B 205M 1.43B 553M 7.02B 538M 526M 22.58B
Net income 10M 11.69M 1.49M 1.32M 1.24M 1.13M 2.12M 143M 2.14M 14.93M 5.75M 73.02M 5.6M 5.47M 235M 50M 58.46M 7.45M 6.58M 6.22M 5.64M 10.58M 715M 10.68M 74.63M 28.76M 365M 27.98M 27.37M 1.17B
Net Debt - -
Logo Cutia Therapeutics
Cutia Therapeutics is an investment holding company principally engaged in the dermatology biopharmaceutical business. The Company is dedicated to developing solutions in the dermatology treatment and care market, including scalp diseases and care, skin diseases and care, topical anesthesia and localized adipose accumulation management. The Company is primarily engaged in the distribution of scalp diseases and care products, as well as certain skin care products. The Company's principal pipeline products include topical finasteride spray CU-40102, topical 4% minocycline foam CU-10201, topical novel small molecule agent CU-10101, localized topical lidocaine and tetracaine cream CU-30101 and recombinant mutant collagenase CU-20401.
Employees
268
Date Price Change Volume
26-09-29 HK$1.100 +22.22% 2,176,800
26-09-28 HK$0.9000 -4.76% 4,018,400
26-09-25 HK$0.9450 -10.00% 235,200
26-09-24 HK$1.050 -0.94% 1,664,200
26-09-23 HK$1.060 -5.78% 233,400
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.9408CNY
Average target price
6.572CNY
Spread / Average Target
+598.58%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2487 Stock